157 results on '"Riboldazzi, G"'
Search Results
2. Prevalence and features of peripheral neuropathy in Parkinson's disease patients under different therapeutic regimens
3. Polymorphisms of dopamine receptor genes and risk of visual hallucinations in Parkinson’s patients
4. Correction to: Effectiveness of Rotigotine plus intensive and goal‑based rehabilitation versus Rotigotine alone in “de‑novo” Parkinsonian subjects: a randomized controlled trial with 18‑month follow‑up
5. Improvement of impulse control disorder and sleep disturbance after switch to rotigotine in Parkinsonʼs disease patients treated with dopamine agonists: 880
6. Multidisciplinary intensive rehabilitation treatment and rotigotine in the early stages of Parkinsonʼs disease: A randomized controlled study: 646
7. Modifications of apoptosis-related protein levels in lymphocytes of patients with Parkinson’s disease. The effect of dopaminergic treatment
8. Comorbid disorders and hospitalisation in Parkinson’s disease: a prospective study
9. Modifications of plasma and platelet levels of L-DOPA and its direct metabolites during treatment with tolcapone or entacapone in patients with Parkinson’s disease
10. BDNF Val66Met polymorphism is associated with cognitive impairment in Italian patients with Parkinson’s disease
11. Long-term experience with continuous duodenal levodopa-carbidopa infusion (Duodopa): report of six patients
12. Correction to: The TANDEM investigation: efficacy and tolerability of levodopa-carbidopa intestinal gel in (LCIG) advanced Parkinson’s disease patients (Journal of Neural Transmission, (2020), 127, 6, (881-891), 10.1007/s00702-020-02175-1)
13. Vortioxetine for the treatment of depressive episodes associated with Parkinson's disease: A case series of six patients
14. Motor complications of Parkinson's disease
15. Design and Operation of the Lombardy Parkinson's Disease Network
16. Effects of dopaminergic stimulation on peripheral markers of apoptosis: relevance to Parkinsonʼs disease
17. Peripheral Markers of Apoptosis in Parkinson's Disease: The Effect of Dopaminergic Drugs
18. Vitamin 25(OH) D and cognitive function in parkinson’s disease
19. PRKAR1B mutation associated with a new neurodegenerative disorder with unique pathology
20. Which patients discontinue? Issues on Levodopa/carbidopa intestinal gel treatment: Italian multicentre survey of 905 patients with long-term follow-up
21. Protein, leucine and vitamin D enhancing rehabilitation (pro-leader) in patients with Parkinson's disease or parkinsonism: a randomized clinical trial
22. Parkinson's disease and reproductive life events
23. Adherence to anti-Parkinson drug therapy in the 'REASON' sample of Italian patients with Parkinson's disease: the linguistic validation of the Italian version of the 'Morisky Medical Adherence Scale-8 items'
24. Reasons driving treatment modification in Parkinson's disease: Results from the cross-sectional phase of the REASON study
25. Clinical variables associated with treatment changes in Parkinson’s disease: results from the longitudinal phase of the REASON study
26. Rehabilitation program with or without a muscle-targeted nutritional support in patients with Parkinson’s disease or parkinsonism: study design of a randomized, controlled trial
27. Reasons driving treatment modification in Parkinson's disease: results from the cross-sectional phase of the REASON study
28. Early DEtection of wEaring off in Parkinson disease: The DEEP study
29. Adverse reaction to COMT inhibitors in Parkinson's disease patients: possible association with the UGTIA9 gene haplotype
30. GIGYF2 mutations are not a frequent cause of familial Parkinson's disease
31. Long-term experience with continuous duodenal levodopa-carbidopa infusion (Duodopa): report of six patients
32. ATP13A2 missense mutations in juvenile parkinsonism and young onset Parkinson disease
33. Brain derived neurotrophic factor plays a role in Parkinson disease clincal features
34. Effectiveness of quetiapine in psychogenic parkinsonism: a case report
35. Comprehensive analysis of the LRRK2 gene in sixty families with Parkinson's disease
36. Clinical features and vascular risk factors in late idiopathic and vascular parkinsonism
37. Functional fibroendoscopy in the study of parkinsonian patients affected by dysphagia
38. Efficacia del trattamento con quetiapina in un caso di parkinsonismo psicogeno
39. Progression to dementia of patients with mild cognitive impairment: relevance of mild parkinsonian signs
40. Novel parkin mutations detected in patients with early-onset Parkinson's disease
41. Expression of apoptosis-related proteins and of dopaminergic receptors in peripheral blood lymphocytes from patients with Alzheimer's disease
42. Use of medical healthcare resources and drug prescription in Parkinson's disease: survey in a cohort of ambulatory patients
43. Parkinson's Disease Comorbidity Study Group. Comorbid disorders and hospitalisation in Parkinson's disease: a prospective study
44. Early DEtection of wEaring off in Parkinson disease: the DEEP study
45. Peripheral markers of apoptosis in parkinson’s disease: the effect of dopaminergic drugs
46. Peripheral markers of apoptosis in Parkinson’s disease: the effect of dopaminergic drugs
47. Utilizzo di risorse sanitarie e terapia farmacologica nella malattia di Parkinson: studio su un gruppo di pazienti ambulatoriali
48. Healthcare utilization and drug therapy in a cohort of Parkinson’s disease ambulatory patients
49. Effetti della terapia dopaminergica su alcuni marcatori periferici di apoptosi nei pazienti con malattia di Parkinson
50. Healthcare use and drug prescription in a cohort of Parkinsonian outpatients
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.